Opioid extended-release tablets with improved tamper-resistant properties

被引:40
作者
Bartholomaeus, Johannes H. [2 ]
Arkenau-Maric, Elisabeth [1 ]
Galia, Eric [1 ]
机构
[1] Grunenthal GmbH, D-52078 Aachen, Germany
[2] Pharmakreativ Consulting, D-52078 Aachen, Germany
关键词
abuse; controlled release; mechanical properties; misuse; opioids; tamper resistant; ABUSE; OXYCODONE;
D O I
10.1517/17425247.2012.698606
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Objective: To prepare a polyethylene oxide-based tablet with high mechanical strength that would release an opioid for once-or twice-daily administration. This tablet would also create barriers against crushing and subsequent preparation steps for abuse and misuse that are not present in conventional opioid formulations. Research design & methods: Innovative manufacturing processes were created by applying heat and force simultaneously, using tramadol HCl as model compound; production scale testing used oxymorphone HCl. Standardized in vitro crush force and extraction tests were performed. Results & discussion: A production scale manufacturing process using hot melt extrusion of a strand, cooling, slicing and shaping the slices into tablet form produced stable oxymorphone extended-release (ER) tablets with in vitro dissolution characteristics similar to commercial oxymorphone ER. The tablets resisted crushing by spoons, pill crushers and a hammer and resisted extraction in a test battery of solvents. The standardized tampering methods used here do not include all methods an abuser might employ. Postmarketing data will be needed to determine the actual impact of tamper resistance mechanisms on opioid abuse rates. Conclusions: This purely mechanical approach to tamper resistance may make a tablet less attractive for abuse without exposing compliant patients to new risks associated with opioid antagonists or aversive compounds. A compliant patient's risk of adverse events may be reduced by the tablet's resistance to accidental crushing.
引用
收藏
页码:879 / 891
页数:13
相关论文
共 36 条
[1]
[Anonymous], 2003, CPMPICH273699
[2]
[Anonymous], 2011, HHS PUBL
[3]
Arkenau-Maric E, 2008, Form of administration secured against misuse, Patent No. [WO20088145334, 20088145334]
[4]
Bartholomaus J, 2011, Tamper-resistant dosage form for oxidation-sensitive opioids, Patent No. [WO2011009603, 2011009603]
[5]
Bartholomaus J, 2011, Method for the production of an abuse-proof, solid form of administration, Patent No. [EP1740156B1, 1740156]
[6]
Bartholomaus J, 2009, Method for the production of an administration form which is secured against misuse, Patent No. [EP1699440B1, 1699440]
[7]
Bartholomaus J, 2007, Dosage form that is safeguarded from abuse, Patent No. [EP1658054B1, 1658054]
[8]
Bartholomaus J, 2007, Form of administration secured against misuse, Patent No. [EP1658055B1, 1658055]
[9]
Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release [J].
Benedek, Irma H. ;
Jobes, Janet ;
Xiang, Qinfang ;
Fiske, William D. .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2011, 5 :455-463
[10]
Black R, 2012, J PAIN, V13, pS58